Related Experiment Video
Updated: Apr 21, 2026
Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis
Published on: May 10, 2024
Novel targeted therapies for eosinophil-associated diseases and allergy
Susanne Radonjic-Hoesli1, Peter Valent, Amy D Klion
1Institute of Pharmacology, University of Bern, CH-3010 Bern, Switzerland;
Abstract:
Eosinophil-associated diseases often present with life-threatening manifestations and/or chronic organ damage. Currently available therapeutic options are limited to a few drugs that often have to be prescribed on a lifelong basis to keep eosinophil counts under control. In the past 10 years, treatment options and outcomes in patients with clonal eosinophilic and other eosinophilic disorders have improved substantially. Several new targeted therapies have emerged, addressing different aspects of eosinophil expansion and inflammation. In this review, we discuss available and currently tested agents as well as new strategies and drug targets relevant to both primary and secondary eosinophilic diseases, including allergic disorders.
Insights
New targeted therapies offer improved outcomes for eosinophil-associated diseases. This review covers current and emerging treatments for eosinophilic disorders, including allergic conditions.
Area of Science:
- Hematology
- Immunology
- Pharmacology
Background:
- Eosinophil-associated diseases can cause severe organ damage and life-threatening symptoms.
- Current treatments are limited, often requiring lifelong management to control eosinophil levels.
Purpose of the Study:
- To review current and emerging therapeutic strategies for eosinophil-associated diseases.
- To discuss novel drug targets for managing eosinophil expansion and inflammation.
Main Methods:
- Literature review of available and investigational agents for eosinophilic disorders.
- Analysis of new treatment strategies and drug targets.
Main Results:
- Significant advancements in treatment options and patient outcomes over the past decade.
- Emergence of several targeted therapies addressing eosinophil biology.
Conclusions:
- Substantial improvements in managing eosinophilic disorders, including clonal eosinophilic diseases.
- Promising new avenues for treating primary and secondary eosinophilic diseases, such as allergic disorders.
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
01:30Allergic Reactions: Anaphylaxis
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:26Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
01:17Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...